ArticleBMC psychiatry2024
Neutrophil/lymphocyte ratio is increased in the acute phase of schizophrenia and regardless the use and types of antipsychotic drugs.
Article in BMC psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Heterogeneity of composite inflammatory markers in acute schizophrenia: stratification by age, gender, and age at onset.European archives of psychiatry and clinical neuroscience · 2026Article
- Article
- Complete blood count-based inflammation indexes and symptom severity in people with bipolar disorder: an analysis based on structural equation modelling.European archives of psychiatry and clinical neuroscience · 2026Article
- Evaluation of Inflammatory Markers in Perception Disorders in Major Psychiatric Pathology.International journal of molecular sciences · 2025Article
- Association of red blood cell count, hemoglobin concentration, and inflammatory indices with cognitive impairment severity in Alzheimer's disease.Scientific reports · 2025Article
- Clinical predictors of short-term treatment response in stupor: a retrospective study.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been found that patients with schizophrenia are often accompanied by concomitant changes in inflammation levels during acute exacerbations, and some studies have suggested that the inflammatory indices neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) may be biomarkers of acute exacerbations in schizophrenia; however, few studies have simultaneously explored the differences in these inflammatory indices in the drug-free patients with schizophrenia in acute phase (DSA), medicated patients with schizophrenia in acute phase (MSA), medicated patients with schizophrenia in remission period (MSR), as well as the effects of different antipsychotic medications on inflammatory indices.
methodA total of 651 subjects including 184 healthy controls (HC), 167 DSA, 119 MSA, and 181 MSR were included in this study. Demographic and disease information was collected from each individual and venous blood was collected to detect immune cells and calculate the inflammatory indices NLR, PLR, and MLR, and statistical methods such as analysis of variance (ANOVA) and multiple comparisons were utilized to explore the alteration of these inflammatory indices under the influence of different antipsychotics and in HC, DSA, MSA, and MSR.
resultsNLR was significantly higher in DSA and MSA than in HC after adjusting the confounders of sex, age, smoking, years of education, marital status, BMI, diabetes, and hypertension. PLR and MLR were not significantly different in patients with schizophrenia and in HC, and were not significantly different in patients with schizophrenia in any group. In MSA and MSR, NLR was positively correlated with disease duration and negatively correlated with the use of mood stabilizers.
conclusionsNLR was significantly increased in acute phase of schizophrenia, regardless of use of antipsychotic drugs, but not significantly increased in stable phase, which might be a promising biomarker for acute phase of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.